Lipid Nanoparticle– tag –
-
Arbutus & Genevant Sue Federal Government for Patent Infringement on Moderna mRNA Vaccine LNP Components
Patent Docs United States Overview On September 11, 2026, Arbutus Biopharma and Genevant Sciences filed a patent infringement lawsuit against the U.S. Federal Government regarding the lipid nanoparticle (LNP) components used in Moderna’s... -
Targeted Nanoparticles Enhance Anti-Cancer Immune Responses, Reprogramming Macrophages via mRNA Technology with Over 60% Reduction in Immunosuppressive Cells
News-Medical Australia Overview Researchers at the University of Adelaide have developed a groundbreaking method using lipid nanoparticles (LNPs) with mRNA technology to reprogram immune cells within tumors, thereby strengthening the bod... -
CRISPR Therapeutics Forges Long-Term Growth with In Vivo Editing and Gene Insertion Following CASGEVY Approval
The Motley Fool USA Overview CRISPR Therapeutics reportedly aims for significant growth over the next decade by building on the commercialization of its approved sickle cell disease and transfusion-dependent beta-thalassemia therapy, CAS... -
Waterfall Scientific Wins Up to $54.5 Million from ARPA-H to Pioneer Continuous-Flow mRNA Manufacturing Platform
Pulse 2.0 USA Overview Waterfall Scientific has been awarded up to $54.5 million from ARPA-H to lead a consortium in developing the ESCALATOR project, a continuous-flow platform for mRNA manufacturing and characterization. This initiativ... -
Moderna’s RSV Vaccine mRESVIA® Receives FDA Approval as mRNA Therapeutics Advance in Non-Vaccine Applications
Facebook (Vaxcyte, Vivaldi Biosciences) USA Overview Moderna's RSV vaccine mRESVIA® gained FDA approval following Breakthrough Therapy Designation, reaffirming the power of mRNA technology in infectious disease prevention. Concurrently, ... -
Recorna and Starna Therapeutics Partner to Advance RNA Gene Editing for Lung Diseases Leveraging STAR LNP Technology
Insight, China's Pharmaceutical Industry China Overview Chinese firms Recorna Biotechnology and Starna Therapeutics have formed a strategic partnership to develop RNA gene editing therapeutics for lung diseases. The collaboration will le... -
Oligonucleotide Drug Delivery Shifts Beyond Liver-Targeting to Tissue-Specific Approaches for Muscle and CNS
GlobeNewswire Unknown Overview Oligonucleotide drug delivery is evolving significantly, moving from traditional liver-targeted strategies to tissue-specific approaches for extrahepatic organs like muscle and the central nervous system (C... -
Rakovina Therapeutics Advances AI Cancer Drug Pipeline with NanoPalm Joint Venture, Nano-Lipid Formulation Data Public Release a 2026 Milestone
Streetwise Reports USA Overview Rakovina Therapeutics is advancing its AI cancer drug pipeline through a proposed joint venture with NanoPalm, combining Rakovina's AI drug discovery capabilities with NanoPalm's self-targeting patterned l... -
Evonik Invests Over C$150 Million in Vancouver LNP Drug Manufacturing Facility, Targeting Late 2029 Launch
Pharmaceutical Outsourcing Canada Overview Evonik is investing over C$150 million (approximately US$110 million) to significantly expand its lipid formulation and lipid nanoparticle (LNP) drug product manufacturing capabilities in Vancou... -
Nanotechnology Revolutionizes Cancer Therapy: Magnetic Nanobots, mRNA Cancer Vaccines, and Gold Nanoparticle Photothermal Treatment Advance
Facebook (Scientific Community Post) Global Overview Nanotechnology is making groundbreaking strides in cancer treatment, with breakthroughs including magnetic nanorobots for targeted drug delivery, mRNA cancer vaccines encapsulated in l...
